
    
      This is a prospective, open-label, Phase II, single-arm interventional trial performed in a
      single center in China. The investigators explore the efficacy and safety of Acetylcysteine
      plus high-dose Dexamethasone in adults newly diagnosed with primary immune thrombocytopenia.
    
  